Loading...
Market
What will be the revenue generated by Clesrovimab in its first full year post-approval by the end of 2025?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Merck's financial disclosures and earnings reports
Story
Merck Announces Positive Phase 2b/3 Results for Clesrovimab in RSV Prevention Trial for Infants
Jul 23, 2024, 12:30 PM
Merck has announced positive topline results from its Phase 2b/3 trial of Clesrovimab (MK-1654), an investigational monoclonal antibody designed to prevent respiratory syncytial virus (RSV) in infants. The antibody-based drug met the main goal of reducing the incidence of lower respiratory infection compared to a placebo in a mid-to-late stage trial. The study, announced on Tuesday, also confirmed the safety profile of the treatment. Merck's announcement highlights the potential of Clesrovimab to protect infants from RSV-related diseases.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Less than $100M • 25%
$100M - $500M • 25%
$500M - $1B • 25%
More than $1B • 25%
Below $500M • 33%
$500M - $1B • 33%
Above $1B • 34%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%